Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), presented new data from two Phase 3 studies, which showed that bazedoxifene/conjugated estrogens reduced the number and severity of hot flashes in symptomatic postmenopausal women by up to 80 percent, when compared with placebo. These data, presented at the North American Menopause Society Annual Meeting, also showed that bazedoxifene/conjugated estrogens improved symptoms of vulvar and vaginal atrophy. [click link for full article]

More: continued here

This entry was posted on Tuesday, October 9th, 2007 at 8:10 am and is filed under Endocrinology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.